These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 9264581)

  • 1. Expression of the farnesyltransferase beta-subunit gene in human ovarian carcinoma: correlation to K-ras mutation.
    Tanimoto H; Mehta KD; Parmley TH; Shigemasa K; Parham GP; Clarke J; O'Brien TJ
    Gynecol Oncol; 1997 Aug; 66(2):308-12. PubMed ID: 9264581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma.
    Shigemasa K; Hu C; West CM; Clarke J; Parham GP; Parmley TH; Korourian S; Baker VV; O'Brien TJ
    J Soc Gynecol Investig; 1997; 4(2):95-102. PubMed ID: 9101469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas.
    Khan SG; Dummer R; Siddiqui J; Bickers DR; Agarwal R; Mukhtar H
    Biochem Biophys Res Commun; 1996 Mar; 220(3):795-801. PubMed ID: 8607844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
    Jamieson S; Alexiadis M; Fuller PJ
    Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum.
    Garrett AP; Ng SW; Muto MG; Welch WR; Bell DA; Berkowitz RS; Mok SC
    Gynecol Oncol; 2000 Apr; 77(1):105-11. PubMed ID: 10739698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased farnesyltransferase activity in human colorectal cancer: relationship with clinicopathological features and K-ras mutation.
    Caruso MG; Notarnicola M; Bifulco M; Laezza C; Guerra V; Altomare DF; Memeo V; Lorusso D; Demma I; Di Leo A
    Scand J Gastroenterol; 2003 Jan; 38(1):80-5. PubMed ID: 12608469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-myc down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor.
    Russo P; Arzani D; Trombino S; Falugi C
    J Pharmacol Exp Ther; 2003 Jan; 304(1):37-47. PubMed ID: 12490573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Cancer Res; 1995 Oct; 55(19):4243-7. PubMed ID: 7671229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ras oncogene activation in human ovarian carcinoma.
    van 't Veer LJ; Hermens R; van den Berg-Bakker LA; Cheng NC; Fleuren GJ; Bos JL; Cleton FJ; Schrier PI
    Oncogene; 1988 Feb; 2(2):157-65. PubMed ID: 3285294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Farnesyltransferase as a target for anticancer drug design.
    Qian Y; Sebti SM; Hamilton AD
    Biopolymers; 1997; 43(1):25-41. PubMed ID: 9174410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy.
    Mok SC; Bell DA; Knapp RC; Fishbaugh PM; Welch WR; Muto MG; Berkowitz RS; Tsao SW
    Cancer Res; 1993 Apr; 53(7):1489-92. PubMed ID: 8384077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
    Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients.
    Cuatrecasas M; Erill N; Musulen E; Costa I; Matias-Guiu X; Prat J
    Cancer; 1998 Mar; 82(6):1088-95. PubMed ID: 9506354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras.
    Brunner TB; Cengel KA; Hahn SM; Wu J; Fraker DL; McKenna WG; Bernhard EJ
    Cancer Res; 2005 Sep; 65(18):8433-41. PubMed ID: 16166322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between K-ras mutation and the expression of p21WAF1/CIP1 and p53 in chronic pancreatitis and pancreatic adenocarcinoma.
    Hermanová M; Lukás Z; Kroupová I; Kleibl Z; Novotný J; Nenutil R; Pazourková M; Brázdil J; Kren L; Díte P
    Neoplasma; 2003; 50(5):319-25. PubMed ID: 14628083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma.
    Isa T; Tomita S; Nakachi A; Miyazato H; Shimoji H; Kusano T; Muto Y; Furukawa M
    Hepatogastroenterology; 2002; 49(45):604-8. PubMed ID: 12063950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of RAS family genes in urothelial carcinoma.
    Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
    J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice.
    Mangues R; Corral T; Kohl NE; Symmans WF; Lu S; Malumbres M; Gibbs JB; Oliff A; Pellicer A
    Cancer Res; 1998 Mar; 58(6):1253-9. PubMed ID: 9515813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.